hATTR clinical trials at UCSF

1 research study open to eligible people

hATTR is a genetic condition where faulty transthyretin protein builds up as amyloid. UCSF is carrying out an observational study that follows people over months and years. UCSF is collecting clinical notes, test results, and blood samples for analysis.

Showing trials for

  • Patients With Transthyretin (ATTR) Amyloidosis

    open to eligible people ages 18-130

    The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

    San Francisco, California and other locations

Last updated: